Arbutus Biopharma (ABUS) Capital Expenditures (2013 - 2024)

Arbutus Biopharma (ABUS) has reported Capital Expenditures for 12 consecutive years, with $86000.0 the latest figure, recorded in Q4 2024.

• Quarterly Capital Expenditures changed N/A year-over-year to $86000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $86000.0 (down 10.42% YoY) and the FY2024 annual result came in at $182000.0, down 81.94% from the prior year.
• Capital Expenditures improved to $86000.0 in Q4 2024 per ABUS's latest filing, from $1000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for ABUS reached as high as $859000.0 in Q2 2023 and fell as low as $1000.0 in Q2 2024.
• A 5-year average of $161176.5 and a median of $91000.0 in 2022 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2021 — Capital Expenditures jumped 857.58% — and 2024, when it tumbled 99.88%.
• Year by year, Capital Expenditures stood at $152000.0 in 2020, then sank by 61.84% to $58000.0 in 2021, then jumped by 131.03% to $134000.0 in 2022, then slumped by 76.12% to $32000.0 in 2023, then soared by 168.75% to $86000.0 in 2024.
• According to Business Quant data, Capital Expenditures over the past three periods registered $86000.0, $1000.0, and $95000.0 for Q4 2024, Q2 2024, and Q1 2024 respectively.